Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Genesis ; 59(7-8): e23435, 2021 08.
Article in English | MEDLINE | ID: mdl-34080769

ABSTRACT

In the spinal cord, ventral interneurons regulate the activity of motor neurons, thereby controlling motor activities including locomotion. Interneurons arise during embryonic development from distinct progenitor domains orderly distributed along the dorso-ventral axis of the neural tube. The p2 progenitor domain generates at least five V2 interneuron populations. However, identification and characterization of all V2 populations remain currently incomplete and the mechanisms that control their development remain only partly understood. In this study, we report the generation of a Vsx1-CreERT2 BAC transgenic mouse line that drives CreERT2 recombinase expression mimicking endogenous Vsx1 expression pattern in the developing spinal cord. We showed that the Vsx1-CreERT2 transgene can mediate recombination in V2 precursors with a high efficacy and specificity. Lineage tracing demonstrated that all the V2 interneurons in the mouse developing spinal cord derive from cells expressing Vsx1. Finally, we confirmed that V2 precursors generate additional V2 populations that are not characterized yet. Thus, the Vsx1-CreERT2 line described here is a useful genetic tool for lineage tracing and for functional studies of the mouse spinal V2 interneurons.


Subject(s)
Eye Proteins/genetics , Gene Targeting/methods , Homeodomain Proteins/genetics , Interneurons/metabolism , Neurogenesis , Spinal Cord/metabolism , Animals , Cell Lineage , Eye Proteins/metabolism , Homeodomain Proteins/metabolism , Integrases/genetics , Integrases/metabolism , Interneurons/cytology , Mice , Mice, Inbred C57BL , Spinal Cord/cytology , Spinal Cord/embryology , Tamoxifen/pharmacology , Transcriptional Activation/drug effects , Transgenes
2.
J Assist Reprod Genet ; 38(1): 151-161, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33184773

ABSTRACT

PURPOSE: To investigate whether adipose tissue-derived stem cells (ASCs) protect the primordial follicle pool, not only by decreasing direct follicle loss but also by modulating follicle activation pathways. METHODS: Twenty nude mice were grafted with frozen-thawed human ovarian tissue from 5 patients. Ten mice underwent standard ovarian tissue transplantation (OT group), while the remaining ten were transplanted with ASCs and ovarian tissue (2-step/ASCs+OT group). Ovarian grafts were retrieved on days 3 (n = 5) and 10 (n = 5). Analyses included histology (follicle count and classification), immunohistochemistry (c-caspase-3 for apoptosis and LC3B for autophagy), and immunofluorescence (FOXO1 for PI3K/Akt activation and YAP for Hippo pathway disruption). Subcellular localization was determined in primordial follicles on high-resolution images using structured illumination microscopy. RESULTS: The ASCs+OT group showed significantly higher follicle density than the OT group (p = 0.01). Significantly increased follicle atresia (p < 0.001) and apoptosis (p = 0.001) were observed only in the OT group. In primordial follicles, there was a significant shift in FOXO1 to a cytoplasmic localization in the OT group on days 3 (p = 0.01) and 10 (p = 0.03), indicating follicle activation, while the ASCs+OT group and non-grafted controls maintained nuclear localization, indicating quiescence. Hippo pathway disruption was encountered in primordial follicles irrespective of transplantation, with nuclear YAP localized in their granulosa cells. CONCLUSION: We demonstrate that ASCs exert positive effects on the ovarian reserve, not only by protecting primordial follicles from direct death but also by maintaining their quiescence through modulation of the PI3K/Akt pathway.


Subject(s)
Forkhead Box Protein O1/genetics , Mesenchymal Stem Cell Transplantation , Microtubule-Associated Proteins/genetics , Ovarian Follicle/transplantation , Adult , Animals , Apoptosis/genetics , Autophagy/genetics , Female , Granulosa Cells/cytology , Granulosa Cells/transplantation , Humans , Mesenchymal Stem Cells/cytology , Mice , Ovarian Reserve/genetics , Ovarian Reserve/physiology , Signal Transduction/genetics
3.
Biomolecules ; 10(11)2020 11 22.
Article in English | MEDLINE | ID: mdl-33266431

ABSTRACT

Current understanding of fibrosis remains incomplete despite the increasing burden of related diseases. Preclinical models are used to dissect the pathogenesis and dynamics of fibrosis, and to evaluate anti-fibrotic therapies. These studies require objective and accurate measurements of fibrosis. Existing histological quantification methods are operator-dependent, organ-specific, and/or need advanced equipment. Therefore, we developed a robust, minimally operator-dependent, and tissue-transposable digital method for fibrosis quantification. The proposed method involves a novel algorithm for more specific and more sensitive detection of collagen fibers stained by picrosirius red (PSR), a computer-assisted segmentation of histological structures, and a new automated morphological classification of fibers according to their compactness. The new algorithm proved more accurate than classical filtering using principal color component (red-green-blue; RGB) for PSR detection. We applied this new method on established mouse models of liver, lung, and kidney fibrosis and demonstrated its validity by evidencing topological collagen accumulation in relevant histological compartments. Our data also showed an overall accumulation of compact fibers concomitant with worsening fibrosis and evidenced topological changes in fiber compactness proper to each model. In conclusion, we describe here a robust digital method for fibrosis analysis allowing accurate quantification, pattern recognition, and multi-organ comparisons useful to understand fibrosis dynamics.


Subject(s)
Fibrosis/pathology , Image Processing, Computer-Assisted/methods , Pattern Recognition, Automated/methods , Algorithms , Animals , Azo Compounds , Collagen/analysis , Collagen/metabolism , Disease Models, Animal , Fibrosis/classification , Fibrosis/metabolism , Kidney/metabolism , Kidney/pathology , Liver/metabolism , Liver/pathology , Lung/metabolism , Lung/pathology , Male , Mice, Inbred C57BL , Staining and Labeling
4.
Int J Mol Sci ; 21(15)2020 Aug 04.
Article in English | MEDLINE | ID: mdl-32759774

ABSTRACT

Vascular hyperpermeability is a determinant factor in the pathophysiology of sepsis. While, AMP-activated protein kinase (AMPK) is known to play a role in maintaining endothelial barrier function in this condition. Therefore, we investigated the underlying molecular mechanisms of this protective effect. α1AMPK expression and/or activity was modulated in human dermal microvascular endothelial cells using either α1AMPK-targeting small interfering RNA or the direct pharmacological AMPK activator 991, prior to lipopolysaccharide (LPS) treatment. Western blotting was used to analyze the expression and/or phosphorylation of proteins that compose cellular junctions (zonula occludens-1 (ZO-1), vascular endothelial cadherin (VE-Cad), connexin 43 (Cx43)) or that regulate actin cytoskeleton (p38 MAPK; heat shock protein 27 (HSP27)). Functional endothelial permeability was assessed by in vitro Transwell assays, and quantification of cellular junctions in the plasma membrane was assessed by immunofluorescence. Actin cytoskeleton remodeling was evaluated through actin fluorescent staining. We consequently demonstrate that α1AMPK deficiency is associated with reduced expression of CX43, ZO-1, and VE-Cad, and that the drastic loss of CX43 is likely responsible for the subsequent decreased expression and localization of ZO-1 and VE-Cad in the plasma membrane. Moreover, α1AMPK activation by 991 protects against LPS-induced endothelial barrier disruption by reinforcing cortical actin cytoskeleton. This is due to a mechanism that involves the phosphorylation of p38 MAPK and HSP27, which is nonetheless independent of the small GTPase Rac1. This results in a drastic decrease of LPS-induced hyperpermeability. We conclude that α1AMPK activators that are suitable for clinical use may provide a specific therapeutic intervention that limits sepsis-induced vascular leakage.


Subject(s)
AMP-Activated Protein Kinases/genetics , Capillary Permeability/genetics , Sepsis/genetics , p38 Mitogen-Activated Protein Kinases/genetics , Antigens, CD/genetics , Cadherins/genetics , Connexin 43/genetics , Endothelial Cells/drug effects , Endothelial Cells/pathology , HSP27 Heat-Shock Proteins/genetics , Humans , Lipopolysaccharides/toxicity , RNA, Small Interfering/pharmacology , Sepsis/pathology , Signal Transduction , Zonula Occludens-1 Protein/genetics
5.
Histochem Cell Biol ; 153(5): 295-306, 2020 May.
Article in English | MEDLINE | ID: mdl-32124009

ABSTRACT

Peroxisomes are ubiquitous organelles formed by peroxisome biogenesis (PB). During PB, peroxisomal matrix proteins harboring a peroxisome targeting signal (PTS) are imported inside peroxisomes by peroxins, encoded by PEX genes. Genetic alterations in PEX genes lead to a spectrum of incurable diseases called Zellweger spectrum disorders (ZSD). In vitro drug screening is part of the quest for a cure in ZSD by restoring PB in ZSD cell models. In vitro PB evaluation is commonly achieved by immunofluorescent staining or transient peroxisome fluorescent reporter expression. Both techniques have several drawbacks (cost, time-consuming technique, etc.) which we overcame by developing a third-generation lentiviral transfer plasmid expressing an enhanced green fluorescent protein fused to PTS1 (eGFP-PTS1). By eGFP-PTS1 lentiviral transduction, we quantified PB and peroxisome motility in ZSD and control mouse and human fibroblasts. We confirmed the stable eGFP-PTS1 expression along cell passages. eGFP signal analysis distinguished ZSD from control eGFP-PTS1-transduced cells. Live eGFP-PTS1 transduced cells imaging quantified peroxisomes motility. In conclusion, we developed a lentiviral transfer plasmid allowing stable eGFP-PTS1 expression to study PB (deposited on Addgene: #133282). This tool meets the needs for in vitro PB evaluation and ZSD drug discovery.


Subject(s)
Green Fluorescent Proteins/genetics , Peroxisomal Targeting Signals/genetics , Peroxisomes/metabolism , Zellweger Syndrome/metabolism , Animals , Cells, Cultured , Fibroblasts/metabolism , Fibroblasts/pathology , Green Fluorescent Proteins/metabolism , Humans , Mice , Zellweger Syndrome/pathology
6.
Reprod Biomed Online ; 37(2): 224-233, 2018 08.
Article in English | MEDLINE | ID: mdl-29807764

ABSTRACT

RESEARCH QUESTION: Does ulipristal acetate (UPA) modify the expression of genes related to apoptosis or the extracellular matrix in uterine myomas and are any modifications associated with a clinical response? DESIGN: Targeted analysis of 176 apoptosis- or extracellular-matrix-related genes was conducted using polymerase chain reaction (PCR) arrays. Relevant results were validated by quantitative PCR. Four groups were established: responsive short-term (one course, n = 9), responsive long-term (two to four courses, n = 9), non-responsive (n = 9), and the control group who was not given any hormone therapy (n = 9). The clinical response was monitored by medical imagery and considered significant when volume reduction was greater than 25%. RESULTS: Compared with untreated myomas, significant changes in expression of four genes were found in UPA-treated myomas. Gene expression of integrin subunit beta 4 was repressed by UPA treatment (fold change [FC] = -12.50, P < 0.001, q < 0.001), tenascin-C expression was downregulated in UPA-responsive patients (FC = -2.50, P = 0.010, q = 0.090), survivin was repressed in short-term UPA-responsive tumours (FC = -7.69, P < 0.001, q = 0.010), and catenin delta 2 gene expression was upregulated in non-responsive myomas (FC = +7.36, P < 0.001, q = 0.010). CONCLUSION: This characterization provides the first molecular distinction between myomas responsive or non-responsive to UPA treatment.


Subject(s)
Gene Expression/drug effects , Leiomyoma/drug therapy , Norpregnadienes/therapeutic use , Uterine Neoplasms/drug therapy , Uterus/drug effects , Female , Humans , Leiomyoma/genetics , Leiomyoma/pathology , Middle Aged , Norpregnadienes/pharmacology , Treatment Outcome , Uterine Neoplasms/genetics , Uterine Neoplasms/pathology , Uterus/pathology
7.
Reprod Biomed Online ; 37(2): 216-223, 2018 08.
Article in English | MEDLINE | ID: mdl-29706284

ABSTRACT

Ulipristal acetate (UPA), a selective progesterone receptor modulator (SPRM), offers new therapeutic options for the clinical management of large uterine fibroids associated with heavy menstrual bleeding or with other moderate or severe symptoms (bulk symptoms, pelvic pain, decreased quality of life). SPRM are synthetic compounds that exert an agonist or antagonist effect on target tissues by their binding to progesterone receptors. UPA reduces fibroid size, controls bleeding in a high percentage of women and significantly improves quality of life. The present review aims to provide insights into UPA indications and its mechanism of action.


Subject(s)
Leiomyoma/drug therapy , Menorrhagia/drug therapy , Norpregnadienes/therapeutic use , Quality of Life , Uterine Neoplasms/drug therapy , Female , Humans , Leiomyoma/complications , Menorrhagia/etiology , Treatment Outcome , Uterine Neoplasms/complications
8.
J Clin Endocrinol Metab ; 103(4): 1566-1573, 2018 04 01.
Article in English | MEDLINE | ID: mdl-29408988

ABSTRACT

Context: Ulipristal acetate (UPA), a selective progesterone receptor modulator, clinically reduces uterine myoma size in 80% of cases. However, the molecular mechanism of action is still poorly understood, as is the reason why 20% of myomas do not respond to treatment. Objective: To elucidate whether matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are associated with myoma volume shrinkage after UPA therapy. Design: Prospective study. Setting: Academic research unit of a university hospital. Patients: Uterine biopsies were obtained from 59 patients with symptomatic myomas undergoing myomectomy, 45 of whom were treated preoperatively with either one or greater than or equal to two, 3-month courses of UPA and 14 not given any hormone therapy to serve as controls. Myoma volume was individually monitored during UPA therapy to determine any substantial clinical response (defined as a reduction in volume of >25%). Three groups were established based on the response to treatment: responsive (R) after one course (n = 12); R after two to four courses (n = 15); and nonresponsive (NR; n = 18). Interventions: UPA treatment given as preoperative management for symptomatic myomas. Main Outcome Measures: MMP and TIMP expression assessed by zymography and immunohistochemistry. Results: Compared with controls and NR myomas, responders showed significantly higher expression levels for MMP-1 (P < 0.0001) and MMP-2 (P = 0.009) and significantly lower expression levels for TIMP-1 (P = 0.040). Conclusions: The correlation found between MMP expression and volume fold change supports the notion that MMPs play a key role in UPA-induced myoma shrinkage.


Subject(s)
Leiomyoma/metabolism , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 2/metabolism , Norpregnadienes/therapeutic use , Tissue Inhibitor of Metalloproteinase-1/metabolism , Uterine Neoplasms/metabolism , Female , Humans , Leiomyoma/drug therapy , Leiomyoma/pathology , Prospective Studies , Tumor Burden , Uterine Neoplasms/drug therapy , Uterine Neoplasms/pathology
9.
Gynecol Obstet Invest ; 83(5): 443-454, 2018.
Article in English | MEDLINE | ID: mdl-29227976

ABSTRACT

OBJECTIVE: To investigate whether ulipristal acetate (UPA) treatment modifies the expression of progesterone receptor (PR), its nuclear cofactors steroid receptor coactivator-1 (SRC1) and nuclear corepressor-1 (NCoR1), prosurvival factor B-cell lymphoma 2 (Bcl-2), and Akt in uterine myomas. PATIENTS: Prospective study of 59 women with symptomatic myomas undergoing myomectomy. Forty-two patients were treated preoperatively with UPA; the remaining 17 were not and they served as controls. METHOD: Tissue microarrays were obtained from surgical specimens and immunohistochemistry was performed. Blinded quantification of expression of PR (PR-A vs. PR-B), coactivator SRC1 and corepressor NCoR1, and prosurvival factor Bcl-2, and Akt and evaluation of Akt phosphorylation levels. RESULTS: Compared with the control group, UPA does not alter PR protein levels or expression patterns in myomas, and the PR-A/PR-B ratio was similar, as well as cytoplasmic or nuclear expression of cofactors SRC1 and NCoR1. Bcl-2 was heterogeneously expressed throughout the samples and no significant modification in expression was evidenced. No significant difference was found in Akt expression and phosphorylation between treated and untreated myomas. CONCLUSION: This study did not find any significant change in the expression of the studied factors in myomas after UPA exposure. In conclusion, various theories on myomas cells proposed on the basis of in vitro studies are not supported in vivo.


Subject(s)
Leiomyoma/metabolism , Nuclear Receptor Coactivator 1/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptors, Progesterone/metabolism , Uterine Neoplasms/metabolism , Adult , Case-Control Studies , Co-Repressor Proteins , Female , Humans , Leiomyoma/drug therapy , Leiomyoma/pathology , Norpregnadienes/therapeutic use , Phosphorylation , Prospective Studies , Protein Isoforms , Receptors, Progesterone/therapeutic use , Uterine Neoplasms/drug therapy , Uterine Neoplasms/pathology
10.
Minerva Ginecol ; 68(3): 313-20, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26930390

ABSTRACT

Uterine fibroids are the most commonly encountered benign uterine tumors in women of reproductive age. As progesterone is known to play a key role in promoting myoma growth, the goal of the study was to analyze the efficacy of selective progesterone receptor modulators (SPRMs). From four studies, it was concluded that UPA (ulipristal acetate) treatment was able to control myoma-associated uterine bleeding in over 90% of cases and significantly reduce myoma volume in more than 80% of women. The results of long-term intermittent therapy (PEARL III and PEARL IV studies) (4 courses of 3 months) demonstrated that more than one course of UPA is able to maximize its potential benefits in terms of control of bleeding and fibroid volume reduction. The treatment was considered safe, even at the level of endometrial changes. With the advent of SPRMs, new algorithms should be discussed, as there is no doubt that there is a place for medical therapy with SPRMs in the current armamentarium of fibroid management.


Subject(s)
Leiomyoma/drug therapy , Receptors, Progesterone/drug effects , Uterine Neoplasms/drug therapy , Female , Humans , Leiomyoma/pathology , Norpregnadienes/administration & dosage , Norpregnadienes/pharmacology , Norpregnadienes/therapeutic use , Progesterone/metabolism , Receptors, Progesterone/metabolism , Uterine Hemorrhage/drug therapy , Uterine Hemorrhage/etiology , Uterine Neoplasms/pathology
11.
Fertil Steril ; 104(2): 426-34.e1, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26003270

ABSTRACT

OBJECTIVE: To study the in vivo mechanisms of action of ulipristal acetate (UPA) on uterine myomas. DESIGN: Retrospective histologic and immunohistochemical (IHC) study of myomas. SETTING: Academic research unit. PATIENT(S): Among 59 women with symptomatic myomas who underwent myomectomy, 42 were treated preoperatively with UPA, while 17 were not. INTERVENTION(S): Histology and IHC were analyzed on tissue microarrays obtained from surgical specimens. MAIN OUTCOME MEASURE(S): Proliferation, apoptosis, extracellular matrix (ECM) remodeling, and matrix metalloproteinase 2 (MMP-2) expression. RESULT(S): Proliferation was low in all conditions, with no statistical difference between groups. Terminal deoxynucleotide transferase-mediated dUTP nick-end labeling assay showed an increase in cell death in UPA-treated myomas compared with untreated myomas, but only after short-term treatment; this was not associated with elevated levels of cleaved caspase-3. After long-term treatment, cell density was higher and the ECM volume fraction lower in UPA-treated myomas than in untreated myomas. MMP-2 expression was found to be increased after treatment, showing the highest level after long-term treatment, compared with untreated myomas. CONCLUSION(S): Regarding sustained clinical volume reduction of myomas, this study strongly points to multifactorial mechanisms of action of UPA, involving: 1) a persistently low cell proliferation rate; 2) a limited period of cell death; and 3) ECM remodeling concomitant with stimulation of MMP-2 expression.


Subject(s)
Contraceptive Agents/administration & dosage , Leiomyoma/drug therapy , Myoma/drug therapy , Norpregnadienes/administration & dosage , Uterine Neoplasms/drug therapy , Adult , Double-Blind Method , Female , Humans , Leiomyoma/diagnosis , Leiomyoma/surgery , Middle Aged , Myoma/diagnosis , Myoma/surgery , Preoperative Care/methods , Treatment Outcome , Uterine Neoplasms/diagnosis , Uterine Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...